| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 58.27 | -0.04 (-0.07%) | 35.99 - 71.56 | 67.0 thousand (Below Avg) |
Market data as of 10:44AM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 58.30 |
|---|---|
| Previous Close | 58.31 |
| Day's Range | 57.76 - 58.55 |
| Market Cap | 8.1B |
| Avg Volume (10 Day) | 1.1M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.05 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
PR Newswire - Friday 06/14/2013 8:00 AM ET
| BMRN | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 14.15% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.09 | |
| LT Debt/Equity | 0.09 | |
| Earnings Yield | -- | |
| Price/Sales | 15.83 |
| Company | Last | Change |
|---|---|---|
| Illumina Inc | 71.88 | +0.27% |
| Onyx Pharmaceuticals Inc | 86.30 | -2.82% |
| Jazz Pharmaceuticals PLC | 69.48 | -0.26% |
| Seattle Genetics Inc | 31.97 | -0.71% |
| Medivation Inc | 47.96 | -1.62% |
Data is delayed by at least 15 min.